- Conditions
- Heart Block Complete, Heart Block Second Degree
- Interventions
- Dexamethasone, No Dexamethasone
- Drug · Other
- Lead sponsor
- The Hospital for Sick Children
- Other
- Eligibility
- 16 Years to 50 Years · Female only
- Enrollment
- 350 participants
- Timeline
- 2020 – 2029
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • San Francisco, California • Denver, Colorado + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1825–1848
of 7,392
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Musculoskeletal Injuries
- Interventions
- PREPARE Initial Clinical Assessment - Pilot (two iterations), PREPARE Initial Clinical Assessment - Pre-Injury (one iteration), PREPARE Initial Clinical Assessment - Post-Injury (up to three iterations), PREPARE Optimized Clinical Assessment
- Other
- Lead sponsor
- Womack Army Medical Center
- Federal
- Eligibility
- 18 Years to 44 Years
- Enrollment
- 2,690 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2028
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Fort Liberty, North Carolina
- Conditions
- Hypogonadism
- Interventions
- TSX-002
- Drug
- Lead sponsor
- TesoRx Pharma, LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Neuroendocrine Tumors, Carcinoma, Small Cell Lung, Neuroendocrine Carcinoma
- Interventions
- PEN-221
- Drug
- Lead sponsor
- Tarveda Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 10
- States / cities
- Fort Myers, Florida • St. Petersburg, Florida • Boston, Massachusetts + 4 more
- Conditions
- Prostate Cancer
- Interventions
- GPI-0100, MUC-2-Globo H-KLH conjugate vaccine
- Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Psoriasis
- Interventions
- Deucravacitinib, Systemic psoriasis medications, No systemic medications
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 15 Years to 50 Years · Female only
- Enrollment
- 833 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Lawrenceville, New Jersey
- Conditions
- Central Serous Chorioretinopathy
- Interventions
- Mifepristone, Placebo
- Drug
- Lead sponsor
- Roger Goldberg, M.D., MBA
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 2
- States / cities
- Walnut Creek, California • Boston, Massachusetts
- Conditions
- Healthy Participants
- Interventions
- AZD6793, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Solid Tumor, Adult
- Interventions
- HTI-1066 dose level 1, HTI-1066 dose level 2, HTI-1066 dose level 3, HTI-1066 dose level 4
- Drug
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Nashville, Tennessee • Houston, Texas
- Conditions
- Breast Neoplasms, Obesity
- Interventions
- Biopsy, Blood draw, Mammogram, MRI
- Procedure
- Lead sponsor
- Tarah J Ballinger, MD
- Other
- Eligibility
- 18 Years to 75 Years · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 3
- States / cities
- Carmel, Indiana • Indianapolis, Indiana
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- GSK1292263, GSK1292263 matching placebo, Sitagliptin
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Chula Vista, California • Miami, Florida + 4 more
- Conditions
- Lung Cancer
- Interventions
- CyPath
- Device
- Lead sponsor
- Biomoda Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 128 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2011
- U.S. locations
- 3
- States / cities
- Waterbury, Connecticut • Newark, Delaware • Albuquerque, New Mexico
- Conditions
- Metastatic Breast Cancer, Recurrent Breast Cancer
- Interventions
- Taselisib, Trastuzumab emtansine, Pertuzumab, Trastuzumab, Paclitaxel
- Drug
- Lead sponsor
- Nancy Lin, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Nashville, Tennessee
- Conditions
- Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v7, Stage IIIC Hepatocellular Carcinoma AJCC v7, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8
- Interventions
- Nivolumab, Sorafenib
- Biological · Drug
- Lead sponsor
- Robin Kate Kelley
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 2
- States / cities
- Sacramento, California • San Francisco, California
- Conditions
- Autism Spectrum Disorder, Neurodevelopmental Disorders
- Interventions
- Not listed
- Lead sponsor
- Coalition for Aligning Science
- Other
- Eligibility
- 0 Years to 18 Years
- Enrollment
- 1,250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2040
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 7 more
- Conditions
- Colorectal Cancer
- Interventions
- Atezolizumab, Bevacizumab, Cobimetinib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • New York, New York • Nashville, Tennessee + 1 more
- Conditions
- Lung Cancer
- Interventions
- Autologous dendritic cell-adenovirus p53 vaccine, Carboplatin, Etoposide
- Biological · Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2014
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL)
- Interventions
- Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), firi-cel (Experimental drug)
- Drug
- Lead sponsor
- CARGO Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 31
- States / cities
- Little Rock, Arkansas • Duarte, California • Los Angeles, California + 24 more
- Conditions
- Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia, Relapsed or Refractory Myelodysplastic Syndrome
- Interventions
- NC525
- Drug
- Lead sponsor
- NextCure, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 11
- States / cities
- Duarte, California • Miami, Florida • Boston, Massachusetts + 6 more
- Conditions
- Metastatic Castration-Resistant Prostate Cancer
- Interventions
- AZD2287, AZD2275, AZD2284
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 12
- States / cities
- Palo Alto, California • San Diego, California • Miami, Florida + 9 more
- Conditions
- KidneyTransplant Recipients, Simultaneous Kidney/Pancreas Recipients, Kidney Transplant Donor
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 1,552 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Minneapolis, Minnesota • Rochester, Minnesota
- Conditions
- Ocular Hypertension, Open Angle Glaucoma
- Interventions
- OTX-TIC
- Drug
- Lead sponsor
- Ocular Therapeutix, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 5
- States / cities
- Petaluma, California • Torrance, California • Roswell, Georgia + 2 more
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Adult T-Cell Leukemia/Lymphoma, Aplastic Anemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Essential Thrombocythemia, Hematopoietic and Lymphatic System Neoplasm, Hodgkin Lymphoma, Multiple Myeloma, Myelodysplastic Syndrome, Myelofibrosis, Myeloid Neoplasm, Non-Hodgkin Lymphoma, Polycythemia Vera, Small Lymphocytic Lymphoma
- Interventions
- Fludarabine, Total-Body Irradiation, Donor Lymphocyte Infusion, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Hematopoietic Cell Transplantation, Melphalan, Bone Marrow Aspiration and Biopsy, Diagnostic Imaging, Biospecimen Collection
- Drug · Radiation · Procedure
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2032
- U.S. locations
- 1
- States / cities
- Philadephia, Pennsylvania
- Conditions
- Primary Myelofibrosis
- Interventions
- Momelotinib
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 237 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 14
- States / cities
- Scottsdale, Arizona • Stanford, California • Aurora, Colorado + 11 more